I think high salaries and bonuses are ok as long as we (as a company) receive the promised milestone payments.
That would make the stock price fly high.
I think that if a company receives cash / milestone payment it should reflect into their share price.
so in the end even retail will benefit as long as the company remains independent (no buy-out).
what do you think?
I'd have preferred a buy-out at $16/share though...it would have been quick money for retail, but maybe they thought 4x bonus on current share price would be too much.
I hope the new MDTX device will not compete with or limit Staccato, but I'm kinda concerned right now...
one thing is for sure....if you accumulate below $5 you can never go wrong.
Sentiment: Strong Buy
and even more important they initiated ADASUVE commercial manufacturing.
Sentiment: Strong Buy
see you at $10+
Sentiment: Strong Buy
when will the milestone payments be paid?
did they disclose the details of the partnership?
will they split the revenue 50-50?
thanks
thanks
I'll be holding my shares for at least another full year.
congrats longs!
are you listening to it?
what did they say?
news about smartphone chips?
thanks!
Sentiment: Strong Buy
what do you guys think the numbers will be?
my guess, earnings will just meet the expectations and good outlook for Q3
Sentiment: Hold
but some day they will surrender and we will fly to $1.50
Sentiment: Strong Buy
i clearly saw blocks in the order of 150k, 40k and 80k shares on the ask side at the opening bell...
someone is desperately trying to keep cappy below $1
Sentiment: Strong Buy
i think VVUS is a bit different just because they had restrictions (REMS) to respect so far.
it might change as soon as April 2013, but again it has nothing to do with my concerns on ARNA
when is about Biotech it doesn't really matter.
agree! a possible buy-out is the only likely event that makes me think of going long here...
revenue and sales are BS in my opinion as we know numbers will be very likely on the low side
I'm not bashing or anything, i've no position right now, i'd like to establish one but not sure which direction yet...that's why i'd like to hear from both longs ans shorts.
I'm just concerned about those things that i mentioned in my previous post.
Belviq is only a bit more effective than placebo and the lesson learn from VVUS is that is very difficult to get people buying your drug even if it's effective...go figure!
I meant patients drop out due to poor efficacy (
how can ARNA be valued at $1.8B?
just curious...
I just experienced that last December on YMI...they have been falling for almost a month then +90% and thats it.
Sentiment: Strong Buy
Europeans don't like amphetamines, fine...but this decision was already priced in.
the market shouldn't overreact today, we still have a bright future.
certainly VVUS is worth more than $1.2B since it has 2 drugs approved and one is already selling. There is at least a company with no drugs on sale that is worth $1.7B (ARNA) go figure...
Sentiment: Strong Buy